Articles by Brandon May
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Circulating tumor DNA accurately reflects tumor burden and may serve as a useful clinical biomarker for risk and outcome in ...
REVEAL is the largest prospective and contemporary cohort of patients with PV in the United States.
The OPTIC study evaluated a response-based dose-reduction strategy to optimize the benefit-risk of a TKI in CP-CML.
In patients with previously treated CLL and SLL, pirtobrutinib was safe and associated with high rates of response.
Three-quarters of evaluable patients experienced complete cytogenetic complete response.
A study has characterized HLH–like manifestations as a CRS variant in certain young patients with leukemia/lymphoma.
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.